The therapeuatic effect of Endostar on soft carotid plaque neovascularization in patients with non-small cell lung cancer.

The therapeuatic effect of Endostar on soft carotid plaque neovascularization in patients with non-small cell lung cancer.
复制标题

恩度对非小细胞肺癌患者颈软斑块新生血管的治疗作用

DOI:
10.1038/srep08956
复制
发表时间:
2015-03-10
期刊:
影响因子:
4.6
通讯作者:
Huang P
Huang P
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Pu Z;Wang Y;Zhang Y;Huang J;Hong Y;He H;Liu C;Chen S;Grayburn PA;Huang P

文献摘要

参考文献

被引文献

相似文献

本研究的目的是利用超声造影(CEUS)研究血管生成抑制剂恩度(Endostar)对非小细胞肺癌(NSCLC)患者颈动脉斑块新生血管的影响。选择 91 名患有软颈动脉斑块的 NSCLC 患者接受 NP 方案(长春瑞滨 + 顺铂)(43 名患者)或 ENP 方案(恩度 + NP)(48 名患者)治疗。在治疗前和治疗后 1 个月使用 CEUS 评估斑块厚度和斑块的新生血管形成。 CEUS 增强强度 (EI) 用于量化斑块新生血管。从招募到治疗后 1 个月,任何组的斑块厚度均无显着变化(所有组均 P > 0.05)。对照组和NP组治疗后1个月斑块EI无明显变化(P>0.05),ENP组治疗后1个月EI显着降低(P<0.01),且治疗后1个月显着低于对照组和NP组(均P<0.001)。这项研究表明,抗血管生成治疗可以减少 NSCLC 患者的颈动脉软斑块新生血管形成。
The purpose of this study was to investigate the effect of the angiogenesis inhibitor Endostar on carotid plaque neovascularization in patients with non-small cell lung cancer (NSCLC) using contrast-enhanced ultrasound (CEUS). Ninety-one patients who had NSCLC with soft carotid plaques were selected for treatment either with the NP regimen (vinorelbine + cisplatin) (43 patients) or with the ENP regimen (Endostar + NP) (48 patients). Plaque thickness and neovascularization of the plaque were assessed before and at 1 month after treatment using CEUS. Enhanced intensity (EI) of CEUS was used for quantification of plaque neovascularization. There was no significant changes in any group in thickness of plaque between recruitment and 1 month after treatment (P > 0.05 for all). There was no significant change in the EI of plaque in the controls or NP groups at 1 month after treatment (P > 0.05), while EI in the ENP group was significantly reduced at 1 month after treatment (P < 0.01) and significantly lower than that in the controls or NP group at 1 month after treatment (P < 0.001 both). This study indicates that carotid soft plaque neovascularization in patients with NSCLC can be reduced by anti-angiogenesis treatment.
DOI: 10.1186/1477-7819-10-170
发表时间: 2012-08-24
影响因子: 3.2
作者:
Rong B;Yang S;Li W;Zhang W;Ming Z
通讯作者: Ming Z
DOI: 10.1093/annonc/mdm550
发表时间: 2008-05-01
期刊: ANNALS OF ONCOLOGY
影响因子: 50.5
作者:
Mourad, J. -J.;des Guetz, G.;Levy, B. I.
通讯作者: Levy, B. I.
DOI: 10.1161/01.cir.99.13.1726
发表时间: 1999-04-06
期刊: CIRCULATION
影响因子: 37.8
作者:
Moulton, KS;Heller, E;Folkman, J
通讯作者: Folkman, J
DOI: 10.1191/1358863x04vm522oa
发表时间: 2004-01-01
期刊: VASCULAR MEDICINE
影响因子: 3.5
作者:
Macioch, JE;Katsamakis, CD;Feinstein, SB
通讯作者: Feinstein, SB
DOI: 10.1016/j.ejphar.2009.04.032
发表时间: 2009-07-01
影响因子: 5
作者:
Ni, Qinggui;Ji, Hui;Xu, Chengyun
通讯作者: Xu, Chengyun